Oncology Live®
November 2012
Volume 13
Issue 11

Surgeon Offers Perspective on Need for GI Navigators


For Johns Hopkins' gastrointestinal cancer surgeon Mark D. Duncan, those who help his patients cope with their diagnosis and manage their often complex treatment and follow-up are critical members of the healthcare team.

Mark D. Duncan, MD, FACS

For Johns Hopkins’ gastrointestinal cancer surgeon Mark D. Duncan, those who help his patients cope with their diagnosis and manage their often complex treatment and follow-up are critical members of the healthcare team–whether they are nurse practitioners, oncology nurses/navigators, or, as in his case, a physician’s assistant. In fact, he would like to see more GI nurse navigators for a specialty where currently there are not enough.

Gastric cancers represent the second-leading cause of cancer deaths worldwide, noted Duncan, MD, FACS, during a presentation at the 4th Annual National Coalition of Oncology Nurse Navigators Changing the Face of Cancer Care Conference, October 4-6 in Nashville, Tennessee. Regardless of the tumor type, “surgery is front and center in these cancers,” and is frequently followed by some complication. At least initially, “all of my patients will lose weight,” and we have to ask ourselves, “If they don’t start to gain weight, is that the effects of surgery, or do they still have cancer?”

“With the tumors I treat, I don’t save most patients, but I treat all,” Duncan said. In getting them back on their feet, “a lot depends on the patient.” His patients tend to be older, with comorbidities to consider. Patients usually come to him with weight loss and malnutrition; fatigue is also an important factor, whether it stems from the effects of aging, the disease itself, or pretreatment of the tumor with radiation or chemotherapy. Radical GI cancer surgery can mean lifelong changes in body function and quality of life–making the patient’s overall fitness, as well as family support, crucial.

Where Does the Navigator Fit In?

Duncan described several of his own surgical cases to illustrate the wide range of issues clinicians confront when treating cancer patients. One typical older patient had to overcome her general distrust of physicians, simultaneously deal with her husband’s illness, and manage the basic logistics of getting to treatment and knowing whom to call with questions. One younger patient raised understandable questions about fertility and sexual activity. A single parent wondered how she could take time off from her job, what to do about her children with her extended family living out of state, and whether to believe what she learned in an Internet chat room versus what her oncologist told her. Other patients must confront language and cultural barriers or cost issues, which can mean missed appointments and difficulties in understanding their diagnosis, treatment, and follow-up care.“The navigator is the glue that holds this all together,” said Duncan, “the secret weapon,” which he said is deployed most effectively in the areas of communication and coordination. This means communicating with patients and doctors, providing resources and guidance, and empowering patients to help set goals for themselves and make treatment decisions. It also means centering care on both patients and their families. “Cancer is personal. It doesn’t just affect patients, it affects people with families,” Duncan said.


While noting “a paucity of hard data” on navigation’s benefits, he cited several recently reported positive outcomes studies, including one by researchers at the Edinburgh Cancer Centre in Scotland (. 2012;21[9]:986-992) who found that navigated patients with prostate cancer were more confident in making treatment decisions, more certain they had made the right decision after consultation, and had fewer regrets about their decision six months later.

Clin J Oncol Nurs

Am J Surg

Looking Ahead

Patients’ Guide to Cancer of the Stomach and Esophagus

When the Connecticut Veterans Affairs HealthcareSystem hired an advanced practice nurseto serve as a cancer care navigator, researchers reported a reduction in the average time from suspicion of cancer to treatment for patients with non-small cell lung cancer (NSCLC) from 136 days in 2003 (before the new position was established) to 55 days in 2010, as well as a trend toward diagnosis of NSCLC at an earlier stage (. 2012;16[1]:29-36). In another study, researchers at the University of Southern California found that oncology nurse navigation proved to be an effective outreach strategy for increasing participation of black patients in cancer research, and may be achieved at nearly half the cost of traditional methods of enrolling patients in clinical trials at cancer centers (. 2012;203[4]:415-422).Duncan said that he would like to see more attention, funding, and advocacy for GI cancers. Such attention might yield more cancer navigators for the specialty. He believes more navigation also would help increase participation in clinical trials among those traditionally underrepresented, and meet the real need of all patients to better understand these cancers and manage their treatments and follow-up care. Toward that end, he has authored a book, , as part of The Johns Hopkins Patients’ Guide series.

Related Videos
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Suneel Kamath, MD
Suneel Kamath, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center